Description
Rasagiline mesylate is an effective therapeutic in the early stages of Parkinon's Disease as it prevents the breakdown of dopamine by irreversibly binding to MAO-B. It has neuroprotective effects and increases the survival of dopaminergic neurons (1). It prevents alpha synculein induced dopaminergic meuronal death and rescues TrkB neurotrophic signaling (2)